公开(公告)号：US20150329556A1

公开(公告)日：2015-11-19

申请号：US14812351

申请日：2015-07-29

申请人： Takeda Pharmaceutical Company Limited

发明人： Jun Terauchi ,  Hiroshi Nara ,  Hideyuki Oki ,  Kenjiro Sato

IPC分类号： C07D495/04

CPC分类号： C07D495/04 ,  C07D217/26 ,  C07D239/90 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04

摘要： The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

摘要翻译： 本发明提供具有基质金属蛋白酶抑制活性的新型酰胺衍生物，可用作药剂，其为式（I）表示的化合物，其中环A为任选取代的含氮杂环，环B为任选的 取代的单环同环或任选取代的单环杂环，Z是N或NR1（R1是氢原子或任选取代的烃基）是单键或双键，R2是氢原子或任选取代的烃基， X是任选取代的具有1-6个原子的间隔基，环C是（1）任选取代的杂环，或（2）除（II）表示的环以外的任选取代的杂环（X'是S，O，SO或 CH2），并且环B和环C中的至少一个具有取代基，条件是N - {（1S，2R）-1-（3,5-二氟苄基）-3 - [（3-乙基苄基）氨基] 2羟丙基} 5,6二甲基4氧代1,4-二氢噻吩并[2,3-d]嘧啶-2 - 甲酰胺或其盐。

公开(公告)号：US10919891B2

公开(公告)日：2021-02-16

申请号：US16608140

申请日：2018-04-26

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Shuji Kitamura ,  Zenichi Ikeda ,  Sachie Morimoto ,  Minoru Ikoma ,  Koji Watanabe ,  Hideki Hirose ,  Takafumi Yukawa ,  Kenjiro Sato

IPC分类号： C07D471/04 ,  A61P9/06 ,  A61P9/12

摘要： The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US11495331B2

公开(公告)日：2022-11-08

申请号：US16766559

申请日：2018-09-10

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  PATCORE, INC.

发明人： Hiroshi Nara ,  Junya Shirai ,  Tatsuki Koike ,  Kenjiro Sato ,  Takaharu Hirayama ,  Hiromi Fukuda ,  Tsutomu Morita ,  Hiromasa Ishihara ,  Kazue Suzuki ,  Hiroki Sakamoto ,  Fumiaki Kikuchi ,  Kenta Tamaki ,  Toru Tanoue ,  Yuichi Horita ,  Takeshi Ueda

IPC分类号： G16H15/00 ,  G16C20/80 ,  G16C20/10

摘要： An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information. According to an embodiment, this document creation assistance server for assisting with the creation of a document comprises: a final product identification part for accepting identification information for identifying a final product generated by synthesizing a plurality of chemical compounds; a chemical equation acquisition part for referring to electronic experiment note data which provides an electronic record of the details of an experiment relating to the synthesis of the chemical compounds, and acquiring a chemical equation for generating the final product associated with the accepted identification information; and a document generation part for generating a document including the acquired chemical equation.

公开(公告)号：US09475822B2

公开(公告)日：2016-10-25

申请号：US14812351

申请日：2015-07-29

申请人： Takeda Pharmaceutical Company Limited

发明人： Jun Terauchi ,  Hiroshi Nara ,  Hideyuki Oki ,  Kenjiro Sato

IPC分类号： C07D495/04 ,  A61K31/519 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  C07D409/14 ,  C07D239/90 ,  C07D413/12 ,  A61P19/02

CPC分类号： C07D495/04 ,  C07D217/26 ,  C07D239/90 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04

摘要： The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl} 5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.